VERTEX PHARMACEUTICALS INC / MA Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $3.1B | — | $1.1B | — | $1.2B | $4.20 |
| Q2 FY202510-Q · 2025-06-30 | -$21.3M | — | $1.0B | — | $1.2B | $3.99 |
| Q1 FY202510-Q · 2025-03-31 | $1.1B | — | $646.3M | — | $630.1M | $2.49 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $24.9B | $7.5B | $4.9B | $17.3B |
| Q2 FY202510-Q | $24.0B | $6.9B | $5.0B | $6.0B |
| Q1 FY202510-Q | $22.9B | $6.4B | $4.7B | $20.7M |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | $1.2B | $1.1B | — | 253,951,475 |
| Q2 FY202510-Q | $1.2B | $1.0B | — | 256,293,058 |
| Q1 FY202510-Q | $630.1M | $646.3M | — | 257,000,000 |
Filings
(4)Methodology
Every figure on this page is pulled directly from VERTEX PHARMACEUTICALS INC / MA's own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].